Abstract | OBJECTIVE: METHODS: In this study, the expression of uPA, uPAR, and PAI-2 mRNA was examined in normal endometrial tissue (n = 16) and endometrial carcinoma tissues (n = 34) by Northern blot analysis. RESULTS: Compared to the controls, the relative abundance of uPAR was significantly elevated in all of the clinical stages of malignancy examined, with a 33-fold increase in mRNA expression from normal endometria to advanced clinical stage carcinomas (Stage III, P < 0.0001). Similarly, uPA was significantly elevated in all clinical stages examined when compared to the normal group, with a 16-fold increase in mRNA expression in advanced stage carcinomas (P < 0.0005). The expression of both uPA and uPAR mRNA also increased with each progression in clinical stage. Expression of the inhibitor, PAI-2, was significantly up-regulated by 5-fold in only the late stages of endometrial tumor development (P < 0.001), while Stage IB and IC carcinomas did not express high levels of PAI-2 mRNA. CONCLUSION:
|
Authors | C Foca, E K Moses, M A Quinn, G E Rice |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 79
Issue 2
Pg. 244-50
(Nov 2000)
ISSN: 0090-8258 [Print] United States |
PMID | 11063652
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2000 Academic Press. |
Chemical References |
- PLAUR protein, human
- Plasminogen Activator Inhibitor 2
- RNA, Messenger
- Receptors, Cell Surface
- Receptors, Urokinase Plasminogen Activator
- Urokinase-Type Plasminogen Activator
|
Topics |
- Endometrial Neoplasms
(genetics, metabolism)
- Endometrium
(metabolism, physiology)
- Female
- Gene Expression
- Gene Expression Regulation, Neoplastic
- Humans
- Plasminogen Activator Inhibitor 2
(biosynthesis, genetics)
- RNA, Messenger
(biosynthesis, genetics)
- Receptors, Cell Surface
(biosynthesis, genetics)
- Receptors, Urokinase Plasminogen Activator
- Reference Values
- Up-Regulation
- Urokinase-Type Plasminogen Activator
(biosynthesis, genetics)
|